OrphoMed is a San Francisco Bay Area based clinical stage pharmaceutical company focused on the development of novel first-in-class dimer conjugates with superior therapeutic profiles. The company is leveraging its proprietary dimer platform technology to address the issues of visceral hypersensitivity and hypermotility in functional gastrointestinal disorders. OrphoMed dimers are protected by composition of matter and method of use patents. OrphoMed is also exploring therapeutic applications and partnering opportunities for other dimer conjugates in its pipeline.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 05/24/17 | $39,000,000 | Series A |
Mario Family Funds Pappas Capital Relativity Healthcare Partners Takeda Ventures  | undisclosed |
